RxDoctor Payments Data

Priyanka Satish, MD

Cardiovascular Disease · Austin, TXNPI 1205358835

Payments from drug & device makers

$3,107in general payments, 2019–2025

Across 89 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$908
  • Abbott$722
  • Amgen$422
  • Boehringer Ingelheim$144
  • Pfizer$140
  • Novo Nordisk$131
  • plus $639 from 9 others

What the payments were for

  • Food & beverage$2,68395%
  • Education$1515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,107 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$81,253
Medicare patients
350
Services billed
1,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab39$35,642
EliquisApixaban20$21,518
OzempicSemaglutide22$19,607
MounjaroTirzepatide13$10,922
NexlizetBempedoic Acid/Ezetimibe13$8,088
Ezetimibe25$1,205
Rosuvastatin Calcium55$730
Atorvastatin Calcium33$407
Metoprolol Succinate37$331
Olmesartan Medoxomil12$231
Amlodipine Besylate30$192
Losartan Potassium17$185
Lisinopril21$163
Furosemide34$117
Isosorbide Mononitrate ErIsosorbide Mononitrate11$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$21,51820 claims
Novo NordiskOzempic$131$19,60722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →